Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs WD 40 Company (WDFC) Price & Performance

Maravai LifeSciences Holdings Inc. Class A Common StockTrade
WD 40 CompanyTrade

Price performance (Past 24H)

Key statistics

Maravai LifeSciences Holdings Inc. Class A Common Stock vs WD 40 Company — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while WD 40 Company trades at $203.62 (market cap $2.74B). The key difference: WD 40 Company is far larger — about 2.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and WD 40 Company pays a 2% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and WD 40 Company for 23 Days on average.

MRVIWDFC
Market Cap
$972.90M$2.74B
Volume
4,325,710121,880
Sector
HealthBasic Materials
52-Week High
$9.00$264.91
52-Week Low
$2.83$187.52
Typical Hold Time
0 Days23 Days
Enterprise Value
$1.08B$2.80B
Dividend Yield
—2%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Maravai LifeSciences Holdings Inc. Class A Common Stock

Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.

The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.

WD 40 Company

WDFC trades at $204.41, up 0.8% today, with a bullish technical signal from moving averages and key resistance at $206. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.33, and maintains robust profitability with a 33.22% ROE. Recent news highlights strategic growth initiatives and institutional buying interest.

Outlook is mixed; solid fundamentals and growth strategy support upside, but high valuation (P/E 31.07) and margin pressures from input costs pose risks. Analyst consensus is cautious with 71% hold ratings, indicating tempered expectations despite operational strength.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MRVI
100% Buy0% Sell
Avg holding period · 0 Days
WDFC

No sentiment data available yet.

Top news

Latest headlines on both assets

About Maravai LifeSciences Holdings Inc. Class A Common Stock

Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.

Read more on MRVI →

About WD 40 Company

WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.

Read more on WDFC →